Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct 29;4(4):e0022.
doi: 10.5041/RMMJ.10129. eCollection 2013.

The Endocannabinoid System, Cannabinoids, and Pain

Affiliations
Free PMC article

The Endocannabinoid System, Cannabinoids, and Pain

Perry G Fine et al. Rambam Maimonides Med J. .
Free PMC article

Abstract

The endocannabinoid system is involved in a host of homeostatic and physiologic functions, including modulation of pain and inflammation. The specific roles of currently identified endocannabinoids that act as ligands at endogenous cannabinoid receptors within the central nervous system (primarily but not exclusively CB 1 receptors) and in the periphery (primarily but not exclusively CB 2 receptors) are only partially elucidated, but they do exert an influence on nociception. Exogenous plant-based cannabinoids (phytocannabinoids) and chemically related compounds, like the terpenes, commonly found in many foods, have been found to exert significant analgesic effects in various chronic pain conditions. Currently, the use of Δ9-tetrahydrocannabinol is limited by its psychoactive effects and predominant delivery route (smoking), as well as regulatory or legal constraints. However, other phytocannabinoids in combination, especially cannabidiol and β-caryophyllene, delivered by the oral route appear to be promising candidates for the treatment of chronic pain due to their high safety and low adverse effects profiles. This review will provide the reader with the foundational basic and clinical science linking the endocannabinoid system and the phytocannabinoids with their potentially therapeutic role in the management of chronic pain.

Keywords: Cannabinoids; cannabinoid receptors; chronic pain; endocannabinoid system; phytocannabinoids.

Figures

Figure 1
Figure 1
The Vicious Cycle of Pain.
Figure 2
Figure 2
Consequences of Unresolved Pain.
Figure 3
Figure 3
Chemical Structures of Anandamide, Δ9-Tetrahydrocannabinol, and Cannabidiol.

Similar articles

See all similar articles

Cited by 19 articles

See all "Cited by" articles

References

    1. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1–32. doi: 10.1146/annurev.neuro.051508.135531. - DOI - PMC - PubMed
    1. IOM Committee on Advancing Pain Research, Care, and Education Board on Health Sciences Policy Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Institute of Medicine of the National Academies, 2011. Available at: http://tinyurl.com/4377gws. Accessed March 23, 2013.
    1. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85:S3–14. - PMC - PubMed
    1. Beaver WT, Buring J, Goldstein A, Johnson K, Jones R. Ad Hoc Group of Experts Report to the Director. Bethesda, MD: National Institutes of Health; 1997. Workshop on the Medical Utility of Marijuana; p. 19.
    1. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6:713–37. doi: 10.1016/j.nurt.2009.08.002. - DOI - PMC - PubMed

LinkOut - more resources

Feedback